Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ACE-083 in Facioscapulohumeral Muscular Dystrophy
2016-003257-15Phase 2Terminated
- Sponsor
- Acceleron Pharma Inc.
- Start
- Jan 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in facioscapulohumeral muscular dystrophy (FSHD) comparing ACE-083 with Placebo (2 arms). Primary endpoint: Primary endpoints (Part 1). Started Jan 2018; status: terminated.
02
Drugs
efmitermant alfa
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on 2016-003257-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003257-15.